A study on global gene expression and circulating mRNA profiling in Esophageal cancer patients
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: - Health Condition 2: C159- Malignant neoplasm of esophagus, unspecified
- Registration Number
- CTRI/2020/05/025172
- Lead Sponsor
- Dr Naveena Kumar A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed with locally advanced esophageal cancer. Age less than 75 years and more than 18 years. Patients who are willing to give informed consent.
Exclusion Criteria
Metastatic esophageal cancer. Patient not fit for neo-adjuvant chemo-radiation and surgery. Patients with seriously ill conditions and major co-morbidities.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gene expression and mRNA profiling in Indian Esophageal Cancer PatientsTimepoint: 3 years
- Secondary Outcome Measures
Name Time Method To assess the survival outcomes in different molecular signatures.Timepoint: 3 years
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link global gene expression to neoadjuvant chemoradiation response in esophageal cancer?
How does circulating mRNA profiling improve patient selection for locally advanced esophageal cancer treatment?
What are the key biomarkers associated with pathologic response in C159 esophageal malignancies following chemoradiation?
Are there comparative studies on gene expression profiling versus traditional imaging for predicting esophageal cancer treatment outcomes?
What adverse events are associated with neoadjuvant chemoradiation in C159 esophageal cancer and how are they managed?